Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on X:
“Excited to share the first results from our Johnson & Johnson Innovation new KLK2xCD3 investigational agent called pasritamig, a first-in-class, Bispecific T-Cell Engager Targeting Human Kallikrein 2 (KLK2) in mCRPC.”
Title: Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study
Authors: Mark N. Stein, Armelle Vinceneux, Debbie Robbrecht, Bernard Doger, Karen A. Autio, Michael T. Schweizer, Emiliano Calvo, Laura Medina, Marloes Van Dongen, Jean-Laurent Deville, Alice Bernard-Tessier, Debopriya Ghosh, Kristin Shotts, Fei Shen, Pharavee Jaiprasart, Ruchi Chaudhary, Shujian Wu, Leanne Cartee, Robert Schnepp, Daria Gaut, Josh Lauring, Sherry C. Wang, Victor M. Villalobos, Capucine Baldini.
Read the Full Article on Journal of Clinical Oncology.
